Search

Search Constraints

You searched for: Author/Creator Herting, Frank

Search Results

1. A re-engineered immunotoxin shows promising preclinical activity in ovarian cancer. Issue 1 (December 2017)

2. Antitumour activity of the glycoengineered type II anti‐CD20 antibody obinutuzumab (GA101) in combination with the MDM2‐selective antagonist idasanutlin (RG7388). (18th April 2016)

4. Characterization of a re‐engineered, mesothelin‐targeted Pseudomonas exotoxin fusion protein for lung cancer therapy. Issue 8 (14th July 2016)

6. Enhanced anti-tumor activity of the glycoengineered type II CD20 antibody obinutuzumab (GA101) in combination with chemotherapy in xenograft models of human lymphoma. Issue 9 (September 2014)

7. Impact of selective anti‐BMP9 treatment on tumor cells and tumor angiogenesis. Issue 10 (20th October 2016)

8. Vaccine-induced CD8 T cells are redirected with peptide-MHC class I-IgG antibody fusion proteins to eliminate tumor cells in vivo. Issue 1 (1st January 2020)